MarketCap
Facebook
X
Telegram
CONMED Corporation Net Income | CNMD
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income CONMED Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.1 M | 132 M | 64.5 M | -80.6 M | 62.5 M | 9.52 M | 28.6 M | 40.9 M | 55.5 M | 14.7 M | 30.5 M | 32.2 M | 35.9 M | 40.5 M | 752 K | 30.3 M | 12.1 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | -80.6 M | 32.8 M |
Quarterly Net Income CONMED Corporation
| 2026-Q2 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.1 M | 2.86 M | 21.4 M | 6.04 M | 49 M | 30 M | 19.7 M | 15.8 M | 13.7 M | 1.82 M | - | 46.2 M | -168 M | 15 M | - | 14.9 M | 13.3 M | 9.86 M | 24.1 M | 6.85 M | -27.4 M | 5.93 M | 14.9 M | 6.97 M | 5.7 M | 1.02 M | 15.7 M | 5.82 M | 8.72 M | 10.7 M | 46.7 M | 7.2 M | 6.14 M | -4.54 M | 6.71 M | 7.34 M | 2.88 M | -2.26 M | 7.85 M | 8.87 M | 7.46 M | 6.31 M | 11.3 M | 1.97 M | 10.3 M | 8.63 M | 10.2 M | 5.69 M | 9.53 M | 10.5 M | 10.9 M | 9.32 M | 10.3 M | 9.97 M | -25.1 M | 8.21 M | 8.68 M | 9 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49 M | -168 M | 7.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Inogen
INGN
|
22.7 M | $ 7.05 | -0.77 % | $ 188 M |  USA |
 |
Bruker Corporation
BRKR
|
-8.3 M | $ 57.98 | 0.68 % | $ 8.8 B | USA |
 |
Boston Scientific Corporation
BSX
|
2.89 B | $ 45.24 | -0.91 % | $ 67 B | USA |
 |
LivaNova PLC
LIVN
|
-242 M | $ 79.76 | -1.41 % | $ 4.35 B |  Britain |
 |
Pulmonx Corporation
LUNG
|
-54 M | $ 1.96 | 7.1 % | $ 79.7 M | USA |
 |
Medtronic PLC
MDT
|
4.8 B | $ 94.3 | -1.14 % | $ 121 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 4.26 | -19.26 % | $ 265 M | USA |
 |
Myomo
MYO
|
-15.6 M | $ 1.2 | -1.64 % | $ 50.2 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-75 M | $ 0.35 | -4.75 % | $ 22.7 M |  Israel |
 |
InspireMD
NSPR
|
-48.8 M | $ 0.47 | 3.69 % | $ 30.2 M | Israel |
 |
Outset Medical
OM
|
-81.7 M | $ 4.07 | -0.85 % | $ 61.9 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | USA |
 |
PAVmed
PAVM
|
-3.77 M | $ 2.26 | 4.15 % | $ 1.52 M | USA |
 |
Penumbra
PEN
|
178 M | $ 324.88 | 0.05 % | $ 12.6 B | USA |
 |
Insulet Corporation
PODD
|
247 M | $ 147.21 | -1.21 % | $ 10.4 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | USA |
 |
AVITA Medical
RCEL
|
-48.6 M | $ 15.23 | -1.8 % | $ 424 M |  Australia |
 |
Inspire Medical Systems
INSP
|
145 M | $ 70.62 | -0.58 % | $ 2.07 B | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.61 | 1.9 % | $ 4.47 M | USA |
 |
Smith & Nephew plc
SNN
|
625 M | $ 30.4 | -1.43 % | $ 26.4 B | Britain |
 |
LENSAR
LNSR
|
-34.3 M | $ 5.99 | -1.4 % | $ 71.6 M | USA |
 |
Sensus Healthcare
SRTS
|
-7.72 M | $ 2.83 | -4.55 % | $ 46.2 M | USA |
 |
Stryker Corporation
SYK
|
849 M | $ 303.8 | -1.15 % | $ 116 B | USA |
 |
Tactile Systems Technology
TCMD
|
19.1 M | $ 23.65 | 0.08 % | $ 541 M | USA |
 |
TELA Bio
TELA
|
-38.8 M | $ 1.01 | 4.66 % | $ 47.4 M | USA |
 |
Tandem Diabetes Care
TNDM
|
-205 M | $ 18.23 | 4.59 % | $ 1.24 B | USA |
 |
Profound Medical Corp.
PROF
|
-42.6 M | $ 5.55 | -0.14 % | $ 168 M |  Canada |
 |
Viemed Healthcare
VMD
|
15.4 M | $ 9.7 | -1.02 % | $ 377 M | USA |
 |
Varex Imaging Corporation
VREX
|
-70.3 M | $ 18.42 | -0.03 % | $ 763 M | USA |
 |
Quanterix Corporation
QTRX
|
-107 M | $ 2.84 | -0.66 % | $ 121 M | USA |
 |
Vivos Therapeutics
VVOS
|
-21.2 M | $ 0.13 | -2.84 % | $ 1.34 M | USA |
 |
Beyond Air
XAIR
|
-33.2 M | $ 2.2 | 5.26 % | $ 18.3 B | USA |
 |
Xtant Medical Holdings
XTNT
|
4.97 M | $ 0.29 | 1.31 % | $ 40.5 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
705 M | $ 96.52 | -2.08 % | $ 19.1 B | USA |
 |
Align Technology
ALGN
|
410 M | $ 151.34 | -2.05 % | $ 11 B | USA |
 |
Abbott Laboratories
ABT
|
6.52 B | $ 104.05 | 0.35 % | $ 181 B | USA |
 |
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 5.91 | -1.91 % | $ 799 M | USA |
 |
Alphatec Holdings
ATEC
|
-143 M | $ 10.96 | -1.4 % | $ 1.64 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | USA |
 |
Bio-Rad Laboratories
BIO
|
760 M | $ 372.06 | 0.45 % | $ 10.1 B | USA |
|
Cognyte Software Ltd.
CGNT
|
-638 K | $ 10.09 | 3.38 % | $ 736 M | Israel |
 |
Electromed
ELMD
|
11.3 M | $ 26.86 | 2.05 % | $ 222 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-51.1 M | $ 66.58 | 4.35 % | $ 1.97 B |  Costa-rica |
 |
IRIDEX Corporation
IRIX
|
-4.44 M | $ 0.74 | -0.75 % | $ 12.5 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 89.91 | 0.91 % | $ 52.6 B | USA |
 |
Helius Medical Technologies
HSDT
|
-40.9 M | $ 2.23 | -1.33 % | $ 49.2 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 23.71 | -3.22 % | $ 556 M | USA |
 |
MiMedx Group
MDXG
|
48.6 M | $ 3.87 | -1.02 % | $ 572 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19 M | - | - | $ 162 M |  France |